Measuring the value of prescription drugs

New England Journal of Medicine

Volumn 373, Issue 27, 2015, Pages 2595-2597

  Neumann, Peter J ^a   Cohen, Joshua T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG; SOFOSBUVIR;

BUDGET; CLINICAL EFFECTIVENESS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MANUFACTURE; GOVERNMENT; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEPATITIS C; HUMAN; MEDICAL SOCIETY; PRIORITY JOURNAL; SHORT SURVEY; SURVIVAL RATE; UNITED STATES; COST BENEFIT ANALYSIS; ECONOMICS; QUALITY ADJUSTED LIFE YEAR;

COST-BENEFIT ANALYSIS; HUMANS; PRESCRIPTION DRUGS; QUALITY-ADJUSTED LIFE YEARS; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84952907922     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1512009     Document Type: Short Survey

References (3)

1. DiJulio B, Firth J, Brodie M. Kaiser Health Tracking Poll: August 2015. Kaiser Family Foundation, August 20, 2015 (http://kff.org/health-costs/poll-finding/kaiser-health-tracking-poll-august-2015).
2. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439-42.
3. New cholesterol drugs are vastly overpriced, analysis says. New York Times. September 9, 2015002E